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Abstract
Hyperhomocysteinemia has been considered a risk factor for neuropsychiatric disorders, but the mechanisms involved in
this process have not been completely elucidated. The aim of this study was to analyze the influence of
hyperhomocysteinemia induction by methionine supplementation considering different levels and periods of exposure
in mice. For this purpose, methionine supplementation at concentrations of 0.5 and 1% were administered in water to
increase homocysteinemia in male C57BL/6 mice, and was maintained for 3 time periods (2, 4 and 6 months of treatment).
The results from one-carbon metabolism parameters, brain-derived neurotrophic factor (BDNF) concentrations and
behavioral evaluation were compared. The 0.5% supplementation was efficient in increasing plasma homocysteine levels
after 2 and 6 months. The 1% supplementation, increased plasma homocysteine after 2, 4 and 6 months. Little influence was
observed in cysteine and glutathione concentrations. Frontal cortex BDNF levels showed a lack of treatment influence in all
periods; only the expected decrease due to increasing age was observed. Moreover, the only behavioral alteration observed
using a novel object recognition task was that which was expected with increasing age. We found that responses to
hyperhomocysteinemia varied based on how it was reached, and the length of toxicity. Moreover, hyperhomocysteinemia
can affect the normal pattern of one carbon metabolism during age increase in mice. These findings allow the
establishment of a reliable animal model for studies in this field.
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Introduction
Hyperhomocysteinemia (HHcy) has been considered a risk
factor for a wide scope of disorders, causing bone development
abnormalities [1], cardiovascular commitment [2,3] and neuro-
psychiatric disorders, such as Alzheimer disease [4], schizophrenia
[5], depression [6] and bipolar disorder [7]. Additionally, the
influence of homocysteine (Hcy) and related molecules in events
ranging from embryologic development [8,9] to aging [10]
demonstrates the relevance of research in this field.
The neurocognitive aspects of HHcy are not completely
understood, but studies have been performed correlating Hcy or
related molecules in the modulation of neurotransmitters and
neural factors, such as dopamine [11], GABA [12], serotonin and
others [13]. Moreover, other factors may also exert important
effects, such as oxidative stress [14,15], exercise [16] and
epigenetic modifications [5].
More recently, brain-derived neurotrophic factor (BDNF) has
been considered to be a possible target for HHcy influence
[13,16], although the mechanisms involved are not completely
understood. Changes in the conversion of S-adenosyl methionine
to S-adenosyl homocysteine or the imbalance in the redox status
[13,17] could also explain BDNF participation in HHcy toxicity.
Considering the well-known oxidative imbalance due to HHcy
[18], it is also possible that Hcy influence is indirect in BDNF
levels [19].
Experimental HHcy models are important tools for investigat-
ing these possibilities, and they are of increasing importance
considering that there are many ways to induce HHcy in animals
[20]. It is possible that different metabolic resources can be used to
avoid accumulation of Hcy in supplementation treatments, which
could lead to different final results, and may or may not affect
BDNF production and function resulting in different behavioral
consequences.
Considering the above statements and the current knowledge
about the cognitive damage caused by Hcy in homocystinuric
patients and how it worsens over time, the aim of this study was to
analyze the impact of Hcy increase over different periods in the
one-carbon metabolic pathway, BDNF and behavioral responses.
To that end, we used 2 supplementation doses to induce HHcy
and analyzed the consequences of its maintenance through 3
periods: 2, 4 and 6 months.
Materials and Methods
2.1. Subjects
Male C57BL/6 mice, 21 days old, were treated with different
concentrations of methionine to increase plasma Hcy concentra-
tions, mimicking a hyperhomocysteinemia condition. The animals
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were exposed to L-methionine at 0.5% (M05) and 1% (M1)
concentrations in drinking water (w/w) [20]. The treatment
persisted for 2, 4 and 6 months. Animals were housed in standard
cages (2 – 5 per cage) in a temperature-controlled room (2262uC)
with a 12:12 h light-dark cycle (light cycle starting at 8 a.m.), and
food and water were provided ad libitum. Animals were exposed to
the same standard chow: water was the only extra source of
methionine. The Institutional Ethical Committee (Comiteˆ de E´tica
em Pesquisa da Universidade Federal de Sa˜o Paulo) approved this
study (CEP: 2012/11), and the mice used were treated according
to the guidelines in the Ethical and Practical Principles of the Use
of Laboratory Animals [21]. During the treatment period, weight,
naso-anal length and pelage conditions were analyzed to check the
animals’ welfare. The Lee index from body mass analysis was
calculated using weight and naso-anal length [22].
During all treatment periods, animals without water supple-
mentation were maintained in the same conditions, which
comprised the control group (CT).
After treatment and behavioral tasks, animals were euthanized
by decapitation. Plasma was separated by centrifugation (10
minutes, 3000 rpm, 4uC) of blood collected in EDTA tubes, and
the frontal cortex was dissected. All of the materials were stored at
-80uC until analysis. A schema of the study is presented in figure 1.
2.2. Behavioral tasks
2.2.1. Locomotor activity. To analyze baseline locomotor
activity, animals were placed in Opto-Varimex cages (Columbus
Instruments, Columbus, Ohio, 47.5625.7620.5 cm), similar to
house cages, where interruptions of horizontal photoelectric beams
were detected and interpreted as activity. Animals were placed in
these cages for 1 hour, and locomotion events were counted each 5
minutes. This experiment always occurred between 4:00 h and
6:00 h (PM).
2.2.2. New object recognition task. As a tool to assess
memory, the ability of the mice to recognize a new object from a
known one was analyzed. Animals were placed in a 20620 cm
empty square, white box for 5 minutes for habituation to decrease
the animals’ exploration of the new environment during the task
[23]. The familiarization phase consisted of placing 2 objects at
opposite corners of the box. For differentiation of the standard
new object recognition task, distinct objects were used because
object properties can influence the degree of animal exploration
and discrimination [24]. One of the objects was a red metal heart-
shaped object (object A), and another was a colorful wood
rectangle (object B). During the test phase, object B was replaced
by a magic cube-like object (object C). The familiarization and test
phases lasted 8 minutes.
All objects were previously tested in an independent animal
group and had similar indexes of preference and common
properties, such as climbing and touching. The experimental
box and objects were cleaned with a 10% ethanol solution after
each phase of animal exposure. Between the habituation,
familiarization and test phases, animals were returned to house
cages and remained there for 10 minutes.
This procedure always occurred between 10:00am and 3:00pm,
and the experiment was recorded by a video camera and
subsequently analyzed by an experimenter that was blind to each
animal’s condition.
The analyzed parameters were as follows: object exploration
time (time animal spent with its nose at least 0.5 cm from object),
rearing (time animal spent in a standing position without leaning
on the box’s walls), leaning (time animal spent upright leaning
against the wall) and grooming [25].
2.3. Biochemical measurements
2.3.1. Plasma and frontal cortex homocysteine, cysteine
and glutathione concentrations. Total plasma and frontal
cortex homocysteine (Hcy), cysteine (Cys) and glutathione (GSH)
concentrations were measured using HPLC (High Performance
Liquid Chromatography) with an isocratic mobile phase and
fluorescence detection at 385 nm excitation and 515 nm emission
[26,27].
For tissue quantification, homogenization with 1x phosphate-
saline buffer (PBS) and protein precipitation with 100 g/L
Figure 1. Representation of treatment and experimental procedures to which animals were exposed. (Hcy = Homocysteine;
Cys = Cysteine; GSH = Glutathione; BDNF = Brain-derived neurotrophic factor).
doi:10.1371/journal.pone.0105704.g001
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trichloroacetic acid with 1 mM EDTA was performed. A
Shimadzu (Shimadzu Corporation, Kyoto, Japan) HPLC system
coupled to a RF-10AXL fluorescence detector was used.
2.3.2. Total protein quantification. Protein quantification
of the frontal cortex was performed to adjust the results of Hcy,
Cys and GSH using the Folin phenol reagent method [28].
2.3.3. BDNF quantification. BDNF quantification was
performed using the ELISA BDNF Emax ImmunoAssay System
kit (Promega, Madison, Wisconsin) with an adaptation to the tissue
lysis method used for protein extraction [29]. This adaptation of
the protocol was required to fit the absorbance detection into the
standard curve range, which corresponds to concentrations
between 500 to 7.8 pg/mL. The obtained absorbance data were
adjusted by the mass of tissue used.
2.4. Statistical Analysis
STATISTICA 7.0 software (Statsoft, Tulsa, Oklahoma) was
used to perform data analysis. Before analysis of variance
(ANOVA), quality tests were conducted to scan normality
(Shapiro-Wilk’s test) and homogeneity (Levene’s test). In cases of
repeated measurements, Mauchly’s sphericity test was also
performed. When required, standardization was performed using
the Z-score.
The Post-hoc test used was Tukey, and p#0.05 was considered
statistically significant. Data are shown as the mean 6 standard
error of mean (SEM).
In the case of repeated measures (weight, length and Lee index),
repeated measures ANOVA was used followed by the Newman-
Keuls post hoc test.
To analyze the relationship between cortical Hcy and BDNF
levels, a correlation test was performed.
Results
3.1. Plasma Hcy, Cys and GSH
With respect to the plasma Hcy concentrations, the responses
were dependent on the dose and duration of treatment. The results
are shown in figure 2.
In this figure, we noted the treatment influence in each period,
but changes over time between controls was also observed (data
not presented in figure 2). A statistically significant reduction was
observed in CT group between 4 and 6 months (p= 0.017), but
this was not observed in the treated groups.
The cysteine and glutathione concentrations for the 3 groups of
treatment duration are presented in table 1.
Slight differences due to treatment could be observed in the
plasma cysteine and glutathione concentrations in each period,
beyond those which could be expected due to increased age. A
reduction in the CT group cysteine concentrations could be
observed, and the differences were significant between 2 and 6
months (p= 0.011) and between 4 and 6 months (p= 0.015). In the
treated groups, the profiles were altered, M05 did not show any
oscillation, and M1 showed an increase between 2 and 4 months
(p= 0.031).
In respect of the GSH concentrations, no difference was
observed in a treatment-dependent manner, but at different time
points, the CT group showed an increase in its levels between 2
and 6 months (p= 0.021). The same profile was observed in the
M05 group (p= 0.049), but no oscillation was detected in the M1
group.
3.2. Biometric parameters
Although an increase in Hcy concentrations was achieved, it
was not sufficient to interfere in bone development and animal
growth. Comparisons of weight, length and the Lee index between
groups did not result in significant differences. The Lee index
results are presented in figure 3.
3.3. Frontal cortex Hcy, Cys and GSH concentrations
In relation to the Hcy concentration in the frontal cortex, a
significant influence was observed just after 2 months of treatment
in the M05 group, but this difference was not observed after 4 or 6
months.
The cortical concentrations of Cys and GSH were not
significantly influenced by treatments in each period – 2, 4 or 6
months – at concentrations of either 0.5 or 1%. The data are
shown in table 2.
Although no overtime oscillations were observed in the Hcy and
Cys concentrations in any group, the treatment with 0.5%
methionine, when analyzed at different time points, appears to
influence GSH concentrations, since this group showed higher
levels after 2 months of treatment when compared to 4 (p= 0.005)
and 6 months (p= 0.044). Interestingly, this difference was not
observed in the CT or M1 groups.
3.4. BDNF quantification
Quantification of BDNF in the frontal cortex showed a lack of
treatment influence in all periods, but in relation to increasing age,
a diminution was observed between 2 and 4 months in the CT
group (p= 0.011). In addition to the CT group, M1 showed a
similar biochemical response (p= 0.041). The same pattern was
observed in the M05 group, but an additional reduction could be
observed between 2 and 6 months (p= 0.000 in both cases). The
results are shown in figure 4.
3.5. Behavioral results
3.5.1. Locomotor activity. In relation to treatment type and
duration, no differences in locomotor activity between treated
groups and CT were observed (data not shown). Furthermore, no
oscillations over time were observed in any group.
3.5.2. New object recognition. The new object recognition
task was analyzed considering not only differential objects
exploration, but also total object exploration, leaning, rearing
and grooming to perform a more global analysis of animal
behavior in this context [25].
With regards to total object exploration, both in familiarization
and in the test, no differences related to treatment were observed.
The results are shown in table 3.
In respect of the variation over time, during familiarization a
significant reduction was observed in the CT group between 2 and
6 months (p= 0.008). Nevertheless, for the M05 group, a
significant decrease was observed earlier, between 2 and 4 months
(p= 0.042), although the difference falls between 2 and 6 months
(p= 0.046). In the M1 group, a reduction was observed only
between 4 and 6 months (p= 0.042).
In the test phase, the CT group showed a significant decrease
between 2 and 6 months (p= 0.002), which also occurs for the
M05 (p= 0.002) and M1 (p= 0.033) groups, but, as in the
familiarization phase, M05 showed an earlier reduction, between 2
and 4 months (p= 0.001) and in M1, between 4 and 6 months
(p= 0.027).
A preferential exploration could be observed in the test phase.
The data are presented in table 4.
Preferential exploration of the new object in the test phase was
expected, and treatment did not result in differences in respect of
this parameter.
The time spent in the new object exploration (object C) is
presented in figure 5. No difference due to the treatment was
Hyperhomocysteinemia in Mice
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found after 2, 4 or 6 months of treatment, but considering the
duration of the treatment, a time-dependent reduction could be
observed. In the CT group, there was a significant reduction
between 2 and 6 months (p= 0.024), but it was different in
experimental groups.
In the M05 group, reduction was observed earlier, between 2
and 4 months (p= 0.008), as well as the 2 and 6 reduction
(p= 0.018). It is interesting to note that in the M1 group, no time-
dependent influence could be observed (p= 0.050).
Secondary behavior analysis showed no treatment or duration
influences in vertical exploration (leaning and rearing sum, data
Figure 2. Plasma homocysteine concentration after 2, 4 and 6 months of treatment with water, methionine 0.5 and 1% solutions.
(N = 9–11). CT = Control. M05 = Methionine 0.5%. M1 = Methionine 1%. * = p#0.05 (Tukey’s post hoc test) when compared with the CT group at the
same period. #= p#0.05 (Tukey’s post hoc test) when compared with the M05 group at the same period. Data are presented as the mean 6 SEM.
doi:10.1371/journal.pone.0105704.g002
Table 1. Cysteine and glutathione (mM) concentrations in plasma after 2, 4 and 6 months of water or 0.5 and 1% methionine
solution treatments.
Cysteine (mM) Glutathione (mM)
2 months CT (N = 10) 354.21617.5 181.44617.7
M05 (N = 10) 310.43614.7 172.08619.4
M1 (N = 10) 297.69611.2 * 192.36616.0
p value (ANOVA) 0.029 0.724
4 months CT (N = 10) 351.42614.2 202.08619.0
M05 (N = 8–9) 317.29612.4 269.15628.1
M1 (N = 9) 348.04613.5 241.47631.4
p value (ANOVA) 0.167 0.218
6 months CT (N = 10) 268.54613.7 257.95619.7
M05 (N = 9–11) 300.52620.9 264.96 31.7
M1 (N = 10–11) 304.69614.2 254.94627.4
p value (ANOVA) 0.723 0.964
CT = Control. M05 = Methionine 0.5%. M1 = Methionine 1%. (N = 9–11). *p = 0.03 (Tukey’s post hoc test) when compared with CT group in same period. Data are
presented as the mean 6 SEM.
doi:10.1371/journal.pone.0105704.t001
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not shown) in the test phase, and when analyzing the ratio between
grooming in the test versus familiarization phase, no treatment or
duration influences were observed.
Discussion
The plasma homocysteine concentrations presented by mice
confirmed the effectiveness of treatments with methionine at both
concentrations to induce HHcy (figure 2) even after only 2 months
of treatment, but a lack of influence was observed after 4 months
in the M05 group. This interesting finding suggests the possibility
of a metabolic effort to address the high intake of methionine and
return to basal levels with greater effectiveness with a lighter
supplementation (0.5%) and shorter duration (4 months). Despite
the same composition, the treatments used in this study had
different influences in metabolism, most likely due to their
concentration differences.
In addition to the treatment influence in each period, it is
important to note that the animals showed changes in the
Figure 3. Lee index results over time (N=10–22). CT = Control. M05 = Methionine 0.5%. M1 = Methionine 1%. Data presented comprise all
animals at the specific time points. Data are presented as the mean 6 SEM.
doi:10.1371/journal.pone.0105704.g003
Table 2. Frontal cortex homocysteine, cysteine and glutathione concentrations (nmol/mg protein) after 2, 4 and 6 months of
hyperhomocysteinemia induced by methionine treatment.
Hcy (1022 nmol/mg protein) Cys (nmol/mg protein) GSH (nmol/mg protein)
2 months CT (N = 8–10) 4.7860.9 5.2060.8 6.1560.6
M05 (N = 9) 10.0361.1 * 5.3960.4 6.7360.4
M1 (N = 6) 9.0762.1 4.6860.6 5.2161.0
p value (ANOVA) 0.020 0.763 0.324
4 months CT (N = 9–10) 9.0761.9 5.5060.7 5.1460.5
M05 (N = 8) 10.3062.2 6.5460.7 4.1360.5#
M1 (N = 4–5) 12.0663.4 6.4061.2 5.5360.6
p value (ANOVA) 0.480 0.582 0.323
6 months CT (N = 3) 9.0162.7 5.8260.7 6.1560.7
M05 (N = 6) 11.7362.3 7.1360.7 4.7160.7#
M1 (N = 7) 10.5062.0 6.6760.3 5.9460.3
p value (ANOVA) 0.967 0.239 0.152
CT = control; M05 = Methionine 0.5%; M1 = Methionine 1%; Hcy = Homocysteine; Cys = Cysteine; GSH = Glutathione. Values presented as the mean 6 SEM. * = Different
from CT group in respective time of treatment (Tukey’s post hoc test, p = 0.02). #= Different from M05 at 2 months (p,0.05)
doi:10.1371/journal.pone.0105704.t002
Hyperhomocysteinemia in Mice
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homocysteine concentration profile over time. In the CT group, a
significant decrease could be associated with the increase in animal
age. This effect has already been described in rats by our group
[30] and is the opposite of the effect reported in humans [31,32].
Moreover, it is interesting to note that this decrease in Hcy
concentrations over time was not observed in the treated groups,
suggesting that an augmentation induced by methionine treatment
in fact coped with the physiological decrease observed in aged
animals. This result points to the possibility that the HHcy
duration, in addition to concentrations reached over time, could
contribute to the HHcy repercussions. Moreover, it is important to
emphasize that there are a number of differences among humans
and rodents concerning one-carbon metabolism [33] that could
impede translational studies.
The treatments established in this study produced a small
influence in plasma cysteine and glutathione concentrations. The
lack of influence can be due to particularities in rodent
metabolism, in which the transsulfuration pathway is highly
activated [33] and glutathione is preferentially produced. It is
important to note that apart from this slight influence, there were
changes in the profile as a result of increased age which could play
a significant role in the HHcy induction models.
Biometrical parameters were not influenced by treatments
(figure 3), which could be due to the mild Hcy concentrations
Figure 4. BDNF quantification in the frontal cortex (N=6–10). CT = Control. M05 = Methionine 0.5%. M1 = Methionine 1%. The results are
presented as the mean 6 SEM.
doi:10.1371/journal.pone.0105704.g004
Table 3. Total object exploration in familiarization and test phases (s) of new object recognition.
Familiarization (s) Test (s)
2 months CT 119.00610.9 122.8969.9
M05 110.5068.2 109.1066.6
M1 99.00614.0 107.44612.0
p value (ANOVA) 0.463 0.475
4 months CT 94.50610.3 93.00613.1
M05 69.11613.8 59.6769.5
M1 108.22611.4 109.22616.8
p value (ANOVA) 0.095 0.051
6 months CT 72.0068.2 62.0067.4
M05 71.90611.5 68.0068.0
M1 63.73612.3 60.3 610.0
p value (ANOVA) 0.812 0.766
CT = control; M05 = Methionine 0.5%; M1 = Methionine 1%. Values presented as the mean 6 SEM.
doi:10.1371/journal.pone.0105704.t003
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reached. It is important to note that in humans the alterations in
these parameters are more related to higher levels of Hcy (e.g. in
homocystinuria) than to HHcy in which plasma concentrations are
set around 100mM [34].
Hcy concentrations in the frontal cortex showed differences
compared to the control group after just 2 months of treatment
with 0.5% methionine (Table 2). This result was not expected,
mainly because a previous study [35] suggested that to reach tissue
Hcy accumulation, longer supplementation is needed. However,
when we observed the concentrations presented at each time
point, the CT group at 2 months had lower values, that became
higher at 4 and 6 months. Despite the natural reduction presented
in circulating Hcy concentrations with the increase of age in mice
(Figure 2), the cortical concentrations were higher and, most
probably because of this, the methionine treatment in the two
doses used was not sufficient to change these values.
It appears that the circulating and tissue Hcy concentrations
have little correlation since in plasma we observed a reduction in
control-aged mice and no changes in the brain. The differences in
these concentrations in mice with increased age point to the
possibility of distinct mechanisms being elicited to handle with
intermediates of one carbon metabolism in different tissues. The
requirement of brain protection from the toxic effects of this amino
acid could lead to a more efficient transsulfuration pathway in
rodents’ nervous tissue to avoid Hcy accumulation, a mechanism
which was maintained even during the aging process, favoring the
formation of GSH (table 2), an antioxidant that has a protective
role against reactive oxygen species [36] and in our study was not
changed after treatment or age increase.
Comparing Hcy and BDNF concentrations in the frontal
cortex, our results indicated that treatment had little influence.
This is emphasized when the correlation test was performed, and
Table 4. Differential exploration of objects A and C in the test phase of new object recognition.
Object A (%) Object C (%) T value p
2 months CT 40.6167.7 59.3967.7 5.485 0.000
M05 35.70610.0 64.30610.0 6.375 0.000
M1 33.9569.1 66.0569.1 7.507 0.000
4 months CT 32.4866.5 67.5266.5 11.975 0.000
M05 30.94613.6 69.06613.6 5.968 0.000
M1 37.6669.9 62.3469.9 5.273 0.0 00
6 months CT 28.6968.6 71.3168.6 10.460 0.000
M05 35.0568.1 64.9568.1 8.644 0.000
M1 31.20610.8 68.80610.8 5.510 0.000
CT = control; M05 = Methionine 0.5%; M1 = Methionine 1%. Values presented as the mean 6.
doi:10.1371/journal.pone.0105704.t004
Figure 5. Time spent in object C (the new object) during the test phase of new object recognition. (N = 8–11). CT = Control.
M05 = Methionine 0.5%. M1 = Methionine 1%. The results presented as the mean 6 SEM.
doi:10.1371/journal.pone.0105704.g005
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no correlation between these variables was observed (r= 0.00).
The lack of changes in the Hcy levels can be due to its metabolism
particularities; in the case of BDNF, it is possible that its levels
were restored in the time point analyzed. A recent study [17]
shows reduced BDNF levels in the hippocampus of rats, which
occurs after acute homocysteine treatment, but it is usually
restored after a short period of time. Furthermore, it is possible
that BDNF, taking into account its importance to life maintenance
[37] and memory processes [38], most likely had protective
pathways to avoid or minimize external influence.
Despite the little influence found, it is noteworthy that plasma
Hcy levels and neurotrophic factors seem to be related [39], but
methodologies vary widely between studies, making results difficult
to compare. More expressive results are usually observed in
knockout models [40] in which there are significant alterations in
various parameters and, also, a severe HHcy is found.
Concerning the behavioral results, we found no differences in
locomotor activity evaluated in the activity box. This result was
important because it served as a control for the new object
recognition test. Differential activity and exploration could be a
bias in new object recognition data interpretation, which was
avoided by the observed locomotor performance. Despite the fact
that we observed no differences in locomotor activity, a
relationship between plasma Hcy and exploration behavior has
been previously described [40], but in knockout animals (Mthfr2/
2), which have more expressive Hcy influence than in our study.
Even considering dietetic manipulations, different responses were
observed. In the B-vitamin-deficient diet locomotor alterations
were observed, despite there being no memory influence [41].
Once again, it is important to highlight how manipulation
influences all results concerning HHcy, since different concentra-
tions and exposition periods were reached.
It is interesting to notice that besides the increase in locomotor
and exploratory behaviors observed in animals with HHcy,
exercise combined with enriched environment applied to cysta-
thionine beta-synthase deficient mice (Cbs +/2) restored molecular
mechanisms responsible for memory impairment and increases
BDNF levels [16].
For exploratory activity, there were no differences observed in
the new object test related to treatment in the familiarization and
test phases. These data show that the animals spent the same
amount of time exploring objects. Analyzing the time spent in total
object exploration, it should be noted that considering the profile
over time, treated animals presented changes, especially the M05
group. This group showed a significant reduction in exploration
earlier than the CT group in both phases. These data suggest that
low performance in this parameter should be anticipated after
treatment, highlighting a treatment influence, manly in the M05
group. It could be due to the marked reduction in BDNF levels
after 4 months of treatment, emphasizing the different responses to
treatment. In relation to differential exploration between objects in
the test phase, an early decrease in object C exploration was
observed in the M05 group, also suggesting that low performance
in this parameter should be anticipated.
Muehlmann and co-workers [42] suggested that stereotyped
behavior, such as grooming, rearing and leaning, could be
indicative of anhedonic or depressive behaviors in animals.
Furthermore, considering the number of studies correlating Hcy
and neuropsychiatric disorders, such as depression in humans [6],
murine depressive-like responses [43] and, anhedonic behavior
[44], one could expect changes in the object exploration test, but
the findings of this study did not corroborate the behavioral effects
of HHcy.
In this study, three different treatment protocols to induce
HHcy were used and produced significant peripheral changes in
the methionine pathway. The central effects of these changes
presented by animals of different groups were less evident. The
molecular mechanisms to explain these differences are under
investigation.
Conclusions
Dose and duration of treatment influenced methionine-induced
hyperhomocysteinemia in different ways, mainly in respect of
peripheral one-carbon metabolism consequences. In relation to
central influences, it has less magnitude but was not negligible.
One-carbon metabolism characteristics are important factors to be
considered in hyperhomocysteinemia studies and could result in a
number of consequences that, in turn, deserve attention in this
research field.
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